SCHEMBL29907476

SCHEMBL29907476

O=C(Nc1ccc(C(O)(C(F)F)C(F)F)cc1)c1cccn(-c2ccccc2OCC(F)(F)F)c1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 6/20 0.81
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
PAX8 Q06710 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
THRB P10828 1/20 0.40
AXL P30530 2/20 0.40
MET P08581 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907357 0.92 UGCG (0.70) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907592 0.90 UGCG (1.00) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907670 0.90 UGCG (0.83) UGCGMAPTSMN1; SMN2KMT2ANPSR1
SCHEMBL24464224 0.87 UGCG (0.81) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907485 0.87 UGCG (0.78) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907364 0.84 UGCG (0.80) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907361 0.84 UGCG (0.89) UGCGMAPTRAB9AKMT2AMEN1
SCHEMBL24464290 0.84 UGCG (0.89) UGCGMAPTRAB9AKMT2AMEN1
SCHEMBL29907394 0.84 UGCG (0.82) UGCGMAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL29907554 0.83 UGCG (0.72) UGCGMAPTSMN1; SMN2RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885MAPT 772/4885SMN1; SMN2 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.